AlphaMark Advisors’s Biogen BIIB Stock Holding History

AlphaMark Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5	Closed	-$1K	–	598
2022 Q3	$1K	Hold	5	–	–	﹤0.01%	622
2022 Q2	$1K	Hold	5	–	–	﹤0.01%	575
2022 Q1	$1K	Sell	5 -12	-71%	-$2.61K	﹤0.01%	573
2021 Q4	$4K	Hold	17	–	–	﹤0.01%	468
2021 Q3	$5K	Hold	17	–	–	﹤0.01%	457
2021 Q2	$6K	Buy	17 +7	+70%	+$2.12K	﹤0.01%	438
2021 Q1	$3K	Buy	+10	New	+$2.7K	﹤0.01%	479
2016 Q4	–	Sell	-4	Closed	-$1K	–	461
2016 Q3	$1K	Hold	4	–	–	﹤0.01%	330
2016 Q2	$1K	Hold	4	–	–	﹤0.01%	320
2016 Q1	$1K	Hold	4	–	–	﹤0.01%	303
2015 Q4	$1K	Hold	4	–	–	﹤0.01%	293
2015 Q3	$1K	Hold	4	–	–	﹤0.01%	279
2015 Q2	$2K	Hold	4	–	–	﹤0.01%	278
2015 Q1	$2K	Buy	+4	New	+$1.58K	﹤0.01%	283
2013 Q4	–	Sell	-344	Closed	-$83K	–	286
2013 Q3	$83K	Hold	344	–	–	0.05%	128
2013 Q2	$74K	Buy	+344	New	+$73.5K	0.05%	145

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

AlphaMark Advisors's BIIB Position: Q4 2022 in Review

AlphaMark Advisors sold out of Biogen (BIIB) in Q4 2022, closing a stake of 5 shares — an estimated $1K sold.

AlphaMark Advisors first reported a position in BIIB in Q2 2013 and held it in 16 quarters. The position peaked at $83K in Q3 2013. 1,031 funds tracked by Wall St. Rank hold BIIB as of Q4 2022.

AlphaMark Advisors reported no remaining Biogen position as of Q4 2022 after selling out during the quarter.
AlphaMark Advisors sold 5 Biogen shares in Q4 2022, an estimated $1K.
AlphaMark Advisors first reported a position in Biogen in Q2 2013 and held it in 16 quarters.
AlphaMark Advisors's Biogen position peaked at $83K in Q3 2013.
1,031 funds tracked by Wall St. Rank held Biogen as of Q4 2022.

Based on AlphaMark Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.